Epitope
Executive Summary
Beaverton, Oregon-based company signs agreement with Smith Kline & French to develop Epitope's proprietary compounds for the treatment of protozoan-caused diseases, including malaria. In return for funding animal and human clinical trials and the purchase of an equity position in Epitope, SK&F receives exclusive world-wide marketing rights except in the U.S., where the drugs will be co-marketed.
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.